Salem Partners, LLC - Investment Banking and Wealth Management
  • Home
  • About
  • Investment Banking
    • Valuation Services
    • Media & Entertainment
    • Healthcare & Life Sciences
    • Industrials
    • Real Estate
    • Specialty & Lender Finance
    • Transactions
  • Wealth Management
    • Portfolio Log In
  • Real Estate Development
  • Professionals
  • News
  • Contact

salem partners announces successful closing of a $130 Million acquisition

4/15/2022

 
Picture
Salem Partners, LLC (“Salem”) is pleased to announce a successful closing of a $130 million acquisition of a brand new 1.1 million square foot, mission critical industrial and distribution facility (the “Property”) 100% leased to Ford Motor Company (“Ford”) in suburban Detroit, MI.

The acquisition closed in April of 2022 between a net-lease focused REIT and the original Property developer. The Property serves as one of the main logistics nodes for Ford’s parts division for North America and was a build-to-suit development by the original developer...(read more)​​

OncoNano Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting

4/13/2022

 
Picture
OncoNano Medicine, Inc. today announced positive results from a preclinical study of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate the efficacy and tolerability of ONM-501 in animal models for multiple tumor types. ONM-501 is formulated with the core OncoNano OMNITM polymer technology consisting of STING-activating pH-sensitive micelles loaded with an endogenous agonist...(read more). 

OncoNano Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting

4/12/2022

 
Picture
OncoNano Medicine, Inc. today announced positive results from the company’s ON-BOARD™ pH-sensitive nanoparticle platform. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that the clinically validated ON-BOARD™ platform has the potential to be a universal tool for tumor-specific activation and the efficient delivery of proteins for an improved therapeutic index.

“Our ON-BOARD micelle platform is designed to efficiently carry a broad range of payloads to the tumor microenvironment. Capable of being tuned to deliver either small molecules or biologics, the ON-BOARD platform has the potential to be a universal tool for targeted delivery of therapeutics to a range of cancers,” said Tian Zhao, Ph.D., Vice President of Research & Development for OncoNano Medicine, Inc...(read more). 

    News

    All
    Aerospace & Defense
    Healthcare & Life Sciences
    Industrials
    Investment Banking
    Media & Entertainment
    Real Estate
    Specialty & Lender Finance
    Wealth Management

    Archives

    December 2022
    April 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    February 2021
    December 2020
    August 2020
    November 2019
    August 2019
    July 2019
    December 2018
    November 2018
    September 2018
    July 2018
    June 2018
    May 2018
    April 2018
    January 2018
    November 2017
    July 2017
    February 2017
    December 2016
    November 2016
    October 2016
    July 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    December 2014
    October 2014
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014
    November 2013
    October 2013
    February 2013
    December 2012
    October 2012
    February 2012
    January 2012
    December 2011
    September 2011
    August 2011
    June 2011
    January 2010
    December 2009
    November 2009
    August 2009
    June 2009
    February 2009
    September 2008
    August 2008
    July 2008
    June 2008
    May 2008
    April 2008
    February 2008
    December 2007
    July 2007
    May 2007
    February 2007
    January 2007
    December 2006
    November 2006
    October 2006

    RSS Feed

© 2016 by Salem Partners LLC - All Rights Reserved. Member FINRA/SIPC.
11111 Santa Monica Blvd. Suite 2250, Los Angeles, CA 90025
Salem Partners, LLC Form CRS